Propanc Biopharma shares surge 12.15% intraday after unveiling PRP proenzyme therapy targeting pancreatic cancer with Phase 1b trials and $10.25B market potential.

Propanc Biopharma surged 12.15% intraday following the announcement of its lead proenzyme therapy PRP, designed to target pancreatic cancer stem cells and inhibit metastasis. The company highlighted preclinical data showing over 85% tumor growth inhibition, FDA Orphan Drug Designation, and plans for a 2026 Phase 1b First-In-Human trial in 30–40 patients with advanced solid tumors. The therapy’s differentiated mechanism—addressing root causes of cancer recurrence and metastasis—positions it as a potential alternative to conventional treatments with significant toxicity. Market projections for the pancreatic cancer treatment sector, expected to grow from $3.25 billion in 2025 to $10.25 billion by 2034, further underscored investor optimism. Strengthened intellectual property and the trial’s alignment with unmet clinical needs in aggressive cancers amplified the stock’s upward momentum.